New Biomarker May Improve Early Detection of Cardiovascular Disease in Kidney Patients
A groundbreaking study suggests that the blood marker SDMA may be a more effective early indicator of cardiovascular issues in chronic kidney disease patients than the traditionally used ADMA, promising earlier detection and intervention.
Recent research conducted by scientists at the University of Texas at Arlington has challenged longstanding beliefs about blood markers associated with vascular health in individuals with chronic kidney disease (CKD). Traditionally, asymmetrical dimethylarginine (ADMA) has been considered a key indicator for vascular issues. However, a new study published in the American Journal of Physiology-Renal Physiology reveals that symmetric dimethylarginine (SDMA), once thought to be an inactive marker, shows a stronger connection to vascular dysfunction in CKD patients.
Led by researcher Paul J. Fadel, the study focused on individuals with stage 3 CKD, aiming to understand how blood vessel function is compromised as the disease progresses, and how these markers can predict cardiovascular risk. While results confirmed that SDMA levels are closely linked to kidney function, they unexpectedly found that SDMA could serve as a more effective early warning sign for vascular problems than ADMA.
"In our study, higher SDMA levels were associated with weaker blood vessel function, suggesting that SDMA might help identify at-risk patients earlier—potentially before they need dialysis," explains Dr. Fadel. This is particularly significant because cardiovascular disease remains the leading cause of death among kidney disease patients. The findings emphasize the potential for SDMA to be incorporated into clinical monitoring to better predict and prevent cardiovascular complications.
Despite these promising results, Fadel notes that the associations observed were modest, and thus SDMA alone may not be a definitive predictor. Further research is necessary to confirm these findings and explore how SDMA can be integrated into routine clinical practice. Overall, this study highlights the importance of reevaluating existing biomarkers and opens new pathways for early intervention strategies in patients with chronic kidney disease.
Source: Medical Xpress
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Elevated Opioid Use During Pregnancy in New Zealand: A Growing Concern
New Zealand ranks third among high-income countries for prescribed opioid use during pregnancy, with nearly 8% of pregnancies affected, raising concerns about potential fetal risks and the need for updated guidelines.
AI Triumphs in Challenging Insurance Denials for Medical Claims
An inspiring story of how AI-powered platforms are empowering patients to successfully challenge insurance claim denials, ensuring vital healthcare coverage.
Enhancing Concussion Care in Community Sports: A Call for Better Return-to-Play Protocols
Researchers highlight the need for improved concussion management and return-to-play protocols in community sports to protect long-term brain health of amateur athletes.